Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Course Instructor
Abby Massey
Capstone Semester
Spring 2022
Date of Graduation
12-16-2022
Abstract
Objective: Assess the efficacy of pravastatin in the prevention or treatment of preeclampsia in women who are at risk. Design: Systematic literature review. Methods: A search was performed using Pubmed utilizing the terms preeclampsia and pravastatin. The results were limited to studies that were double blind and placebo controlled and that occurred in the last 5 years. Results: None of the studies found statistical significance in the rate of preeclampsia between the experimental and control groups. Only one study found statistically significant differences in fetal birth weight and age at delivery. The other two studies found no differences between groups in severity of preeclampsia, gestational age, fetal birth weight and sFlt-1 levels. The studies found no harm was caused by the Pravastatin when given during pregnancy. Conclusion: These studies established preliminary safety and pharmacokinetics with the use of Pravastatin in pregnancy. The significance of the difference in the administration of Pravastatin in pregnancy could not be established in any of the studies. In order to establish any benefits of Pravastatin during pregnancy larger studies must be performed.
Document Type
Capstone
Recommended Citation
Riley, T. Shelly, M. The Safety and Efficacy of Pravastatin in the Treatment of Preeclampsia. 2021. Published December 2022.
